HilleVax downgraded by Leerink Partners with a new price target

7/9/24 9:48:14 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HLVX

Date	Price Target	Rating	Analyst
7/9/2024	$28.00 → $2.00	Outperform → Market Perform	Leerink Partners
7/9/2024	$34.00 → $3.00	Buy → Hold	Stifel
7/9/2024	$28.00 → $2.00	Buy → Neutral	H.C. Wainwright
7/8/2024		Buy → Neutral	Guggenheim
7/8/2024	$24.00 → $5.00	Overweight → Neutral	JP Morgan
12/13/2023	$28.00	Buy	H.C. Wainwright